Effects of antipsychotic medication on psychiatric service utilization and cost

Aileen Rothbard, Mary Rose Murrin, Neil Jordan, Eri Kuno, Bentson McFarland, T. Scott Stroup, Joseph P. Morrissey, Paul G. Stiles, Roger A. Boothroyd, Elizabeth Merwin, David L. Shern

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background: Based on randomized clinical trials, consensus has been emerging that the first line of treatment for individuals with psychotic disorders should be the newer atypical or second generation antipsychotic medications rather than the older neuroleptics. Given that acquisition costs of atypical antipsychotics are generally higher than typical antipsychotics, uncertainty exists whether the newer atypicals are cost effective alternatives when used in ordinary practice settings. Aims of the study: The introduction of newer atypical antipsychotic agents has prompted evaluation of their overall effectiveness in reducing health care costs given their higher acquisition costs. This paper focuses on the effects of differing classes of atypical versus typical antipsychotic medications on psychiatric service utilization and cost for persons with serious mental illness treated in usual practice settings. Methods: Descriptive statistics are used to compare patient characteristics, service rates and costs across psychotropic medication groups. Prediction equations employing ordinary least squares regression models are used to explain variation in cost due to pharmacy group membership controlling for demographics, clinical diagnoses and symptoms. Subjects were 338 Medicaid clients with serious mental illness from Florida, Pennsylvania and Oregon treated in ordinary clinical settings. Resource utilization and costs were operationalized using administrative databases to measure consumption of treatment services and pharmaceuticals for a six month period. Results: Inpatient service use was significantly higher for individuals on atypical only and combination atypical/typical medications compared to those on typical medications only, whereas outpatient use was highest for those on typicals. Furthermore, six-month costs for both pharmacy and psychiatric services were significantly greater for persons in the atypical only ($6528) and combination typical/atypical groups ($6589) compared to those on typicals only ($3463). There were still significantly higher costs associated with atypical only and the combination typical/atypical users after multivariate controls were used. Discussion: This study showed that Medicaid clients in community settings using atypical only and typical/atypical combination medications had the highest costs both in pharmacy and service use when compared to those on typical only medications. However, this study design does not allow us to ascribe a causal relationship between medication group and service costs. Given that olanzapine was the most recent medication in the compendium of available drugs at the time of this study, it is possible that those in the olanzapine only group were failing on other drugs. Caution must be used in drawing policy implications regarding cost effectiveness of newer medications since individuals who are getting the newer atypical or combination medications in community mental health center settings may be unstable on the older medications. Implications for Future Research: A longer follow-up period is needed to determine if the cohort remaining on current atypical medications stabilize over time while those taking the newest drug on the market become the most costly population.

Original languageEnglish (US)
Pages (from-to)83-93
Number of pages11
JournalJournal of Mental Health Policy and Economics
Volume8
Issue number2
StatePublished - Jun 2005

Fingerprint

Antipsychotic Agents
Psychiatry
Costs and Cost Analysis
olanzapine
Pharmaceutical Services
Medicaid
Pharmaceutical Preparations
Community Mental Health Centers
Time and Motion Studies
Least-Squares Analysis
Health Care Costs
Psychotic Disorders
Uncertainty
Cost-Benefit Analysis
Inpatients
Consensus
Outpatients
Randomized Controlled Trials
Demography
Databases

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Psychiatry and Mental health

Cite this

Rothbard, A., Murrin, M. R., Jordan, N., Kuno, E., McFarland, B., Stroup, T. S., ... Shern, D. L. (2005). Effects of antipsychotic medication on psychiatric service utilization and cost. Journal of Mental Health Policy and Economics, 8(2), 83-93.

Effects of antipsychotic medication on psychiatric service utilization and cost. / Rothbard, Aileen; Murrin, Mary Rose; Jordan, Neil; Kuno, Eri; McFarland, Bentson; Stroup, T. Scott; Morrissey, Joseph P.; Stiles, Paul G.; Boothroyd, Roger A.; Merwin, Elizabeth; Shern, David L.

In: Journal of Mental Health Policy and Economics, Vol. 8, No. 2, 06.2005, p. 83-93.

Research output: Contribution to journalArticle

Rothbard, A, Murrin, MR, Jordan, N, Kuno, E, McFarland, B, Stroup, TS, Morrissey, JP, Stiles, PG, Boothroyd, RA, Merwin, E & Shern, DL 2005, 'Effects of antipsychotic medication on psychiatric service utilization and cost', Journal of Mental Health Policy and Economics, vol. 8, no. 2, pp. 83-93.
Rothbard A, Murrin MR, Jordan N, Kuno E, McFarland B, Stroup TS et al. Effects of antipsychotic medication on psychiatric service utilization and cost. Journal of Mental Health Policy and Economics. 2005 Jun;8(2):83-93.
Rothbard, Aileen ; Murrin, Mary Rose ; Jordan, Neil ; Kuno, Eri ; McFarland, Bentson ; Stroup, T. Scott ; Morrissey, Joseph P. ; Stiles, Paul G. ; Boothroyd, Roger A. ; Merwin, Elizabeth ; Shern, David L. / Effects of antipsychotic medication on psychiatric service utilization and cost. In: Journal of Mental Health Policy and Economics. 2005 ; Vol. 8, No. 2. pp. 83-93.
@article{fea4fe2b29d84a248e2ccfc2ebc268e3,
title = "Effects of antipsychotic medication on psychiatric service utilization and cost",
abstract = "Background: Based on randomized clinical trials, consensus has been emerging that the first line of treatment for individuals with psychotic disorders should be the newer atypical or second generation antipsychotic medications rather than the older neuroleptics. Given that acquisition costs of atypical antipsychotics are generally higher than typical antipsychotics, uncertainty exists whether the newer atypicals are cost effective alternatives when used in ordinary practice settings. Aims of the study: The introduction of newer atypical antipsychotic agents has prompted evaluation of their overall effectiveness in reducing health care costs given their higher acquisition costs. This paper focuses on the effects of differing classes of atypical versus typical antipsychotic medications on psychiatric service utilization and cost for persons with serious mental illness treated in usual practice settings. Methods: Descriptive statistics are used to compare patient characteristics, service rates and costs across psychotropic medication groups. Prediction equations employing ordinary least squares regression models are used to explain variation in cost due to pharmacy group membership controlling for demographics, clinical diagnoses and symptoms. Subjects were 338 Medicaid clients with serious mental illness from Florida, Pennsylvania and Oregon treated in ordinary clinical settings. Resource utilization and costs were operationalized using administrative databases to measure consumption of treatment services and pharmaceuticals for a six month period. Results: Inpatient service use was significantly higher for individuals on atypical only and combination atypical/typical medications compared to those on typical medications only, whereas outpatient use was highest for those on typicals. Furthermore, six-month costs for both pharmacy and psychiatric services were significantly greater for persons in the atypical only ($6528) and combination typical/atypical groups ($6589) compared to those on typicals only ($3463). There were still significantly higher costs associated with atypical only and the combination typical/atypical users after multivariate controls were used. Discussion: This study showed that Medicaid clients in community settings using atypical only and typical/atypical combination medications had the highest costs both in pharmacy and service use when compared to those on typical only medications. However, this study design does not allow us to ascribe a causal relationship between medication group and service costs. Given that olanzapine was the most recent medication in the compendium of available drugs at the time of this study, it is possible that those in the olanzapine only group were failing on other drugs. Caution must be used in drawing policy implications regarding cost effectiveness of newer medications since individuals who are getting the newer atypical or combination medications in community mental health center settings may be unstable on the older medications. Implications for Future Research: A longer follow-up period is needed to determine if the cohort remaining on current atypical medications stabilize over time while those taking the newest drug on the market become the most costly population.",
author = "Aileen Rothbard and Murrin, {Mary Rose} and Neil Jordan and Eri Kuno and Bentson McFarland and Stroup, {T. Scott} and Morrissey, {Joseph P.} and Stiles, {Paul G.} and Boothroyd, {Roger A.} and Elizabeth Merwin and Shern, {David L.}",
year = "2005",
month = "6",
language = "English (US)",
volume = "8",
pages = "83--93",
journal = "Journal of Mental Health Policy and Economics",
issn = "1091-4358",
publisher = "ICMPE",
number = "2",

}

TY - JOUR

T1 - Effects of antipsychotic medication on psychiatric service utilization and cost

AU - Rothbard, Aileen

AU - Murrin, Mary Rose

AU - Jordan, Neil

AU - Kuno, Eri

AU - McFarland, Bentson

AU - Stroup, T. Scott

AU - Morrissey, Joseph P.

AU - Stiles, Paul G.

AU - Boothroyd, Roger A.

AU - Merwin, Elizabeth

AU - Shern, David L.

PY - 2005/6

Y1 - 2005/6

N2 - Background: Based on randomized clinical trials, consensus has been emerging that the first line of treatment for individuals with psychotic disorders should be the newer atypical or second generation antipsychotic medications rather than the older neuroleptics. Given that acquisition costs of atypical antipsychotics are generally higher than typical antipsychotics, uncertainty exists whether the newer atypicals are cost effective alternatives when used in ordinary practice settings. Aims of the study: The introduction of newer atypical antipsychotic agents has prompted evaluation of their overall effectiveness in reducing health care costs given their higher acquisition costs. This paper focuses on the effects of differing classes of atypical versus typical antipsychotic medications on psychiatric service utilization and cost for persons with serious mental illness treated in usual practice settings. Methods: Descriptive statistics are used to compare patient characteristics, service rates and costs across psychotropic medication groups. Prediction equations employing ordinary least squares regression models are used to explain variation in cost due to pharmacy group membership controlling for demographics, clinical diagnoses and symptoms. Subjects were 338 Medicaid clients with serious mental illness from Florida, Pennsylvania and Oregon treated in ordinary clinical settings. Resource utilization and costs were operationalized using administrative databases to measure consumption of treatment services and pharmaceuticals for a six month period. Results: Inpatient service use was significantly higher for individuals on atypical only and combination atypical/typical medications compared to those on typical medications only, whereas outpatient use was highest for those on typicals. Furthermore, six-month costs for both pharmacy and psychiatric services were significantly greater for persons in the atypical only ($6528) and combination typical/atypical groups ($6589) compared to those on typicals only ($3463). There were still significantly higher costs associated with atypical only and the combination typical/atypical users after multivariate controls were used. Discussion: This study showed that Medicaid clients in community settings using atypical only and typical/atypical combination medications had the highest costs both in pharmacy and service use when compared to those on typical only medications. However, this study design does not allow us to ascribe a causal relationship between medication group and service costs. Given that olanzapine was the most recent medication in the compendium of available drugs at the time of this study, it is possible that those in the olanzapine only group were failing on other drugs. Caution must be used in drawing policy implications regarding cost effectiveness of newer medications since individuals who are getting the newer atypical or combination medications in community mental health center settings may be unstable on the older medications. Implications for Future Research: A longer follow-up period is needed to determine if the cohort remaining on current atypical medications stabilize over time while those taking the newest drug on the market become the most costly population.

AB - Background: Based on randomized clinical trials, consensus has been emerging that the first line of treatment for individuals with psychotic disorders should be the newer atypical or second generation antipsychotic medications rather than the older neuroleptics. Given that acquisition costs of atypical antipsychotics are generally higher than typical antipsychotics, uncertainty exists whether the newer atypicals are cost effective alternatives when used in ordinary practice settings. Aims of the study: The introduction of newer atypical antipsychotic agents has prompted evaluation of their overall effectiveness in reducing health care costs given their higher acquisition costs. This paper focuses on the effects of differing classes of atypical versus typical antipsychotic medications on psychiatric service utilization and cost for persons with serious mental illness treated in usual practice settings. Methods: Descriptive statistics are used to compare patient characteristics, service rates and costs across psychotropic medication groups. Prediction equations employing ordinary least squares regression models are used to explain variation in cost due to pharmacy group membership controlling for demographics, clinical diagnoses and symptoms. Subjects were 338 Medicaid clients with serious mental illness from Florida, Pennsylvania and Oregon treated in ordinary clinical settings. Resource utilization and costs were operationalized using administrative databases to measure consumption of treatment services and pharmaceuticals for a six month period. Results: Inpatient service use was significantly higher for individuals on atypical only and combination atypical/typical medications compared to those on typical medications only, whereas outpatient use was highest for those on typicals. Furthermore, six-month costs for both pharmacy and psychiatric services were significantly greater for persons in the atypical only ($6528) and combination typical/atypical groups ($6589) compared to those on typicals only ($3463). There were still significantly higher costs associated with atypical only and the combination typical/atypical users after multivariate controls were used. Discussion: This study showed that Medicaid clients in community settings using atypical only and typical/atypical combination medications had the highest costs both in pharmacy and service use when compared to those on typical only medications. However, this study design does not allow us to ascribe a causal relationship between medication group and service costs. Given that olanzapine was the most recent medication in the compendium of available drugs at the time of this study, it is possible that those in the olanzapine only group were failing on other drugs. Caution must be used in drawing policy implications regarding cost effectiveness of newer medications since individuals who are getting the newer atypical or combination medications in community mental health center settings may be unstable on the older medications. Implications for Future Research: A longer follow-up period is needed to determine if the cohort remaining on current atypical medications stabilize over time while those taking the newest drug on the market become the most costly population.

UR - http://www.scopus.com/inward/record.url?scp=21244454774&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21244454774&partnerID=8YFLogxK

M3 - Article

C2 - 15998980

AN - SCOPUS:21244454774

VL - 8

SP - 83

EP - 93

JO - Journal of Mental Health Policy and Economics

JF - Journal of Mental Health Policy and Economics

SN - 1091-4358

IS - 2

ER -